

terms of specificity and sensibility (Sp 100%, Sn 77,6%) to identify frail group. 36% of patients resulted frail. Frailty was associated with longer hospitalization after surgery (11,5 days vs 8,3 days, $p = 0,01$). No differences occurred in the incidence of post-operative adverse events, but grade III and IV complications were observed exclusively in 2 frail women. Only 38,5% of frail patients completed chemotherapy treatment; delay in chemotherapy administration has been reported in 77% of frail patients (vs 17,6% in 'fit group', $p = 0,008$) and dose reduction in 70,6%. Thrombocytopenia (69.3% vs 0%, $p = 0,002$) and anemia (77% vs 29.4%, $p = 0,002$) were more prevalent in the frail group, as well as non-hematological adverse events.

Conclusions Our tool seems to effectively stratify elderly patients with gynecological cancers according to frailty, in order to choose the best treatment for frail women and avoid undertreatment in fit ones.

IGCS20_1122

144 OVARIAN CARCINOMA LONG-TERM SURVIVORS: A LARGE SINGLE CENTER STUDY AT THE TüBINGEN UNIVERSITY WOMEN'S HOSPITAL

¹S Mittelstadt*, ¹M Grube, ¹T Engler, ¹CB Walter, ¹E Oberlechner, ¹J Pasternak, ¹U Hurst, ¹B Krämer, ¹E Grischke, ¹SY Brucker, ²AK Fischer, ²A Staebler, ¹A Hartkopf, ¹S Kommos. ¹Department of Women's Health, Tübingen University Hospital, Germany; ²Department of Pathology and Neuropathology, Tübingen University Hospital, Germany

10.1136/ijgc-2020-IGCS.124

Introduction/Objectives Most ovarian carcinoma patients present with advanced-stage disease and outcome is fatal in many cases. However, the biological behavior of ovarian carcinoma can be quite variable and long-term survival is reported in up to 30% of patients. It is the aim of this project to identify characteristics associated with long-term survival.

Methods Patients diagnosed with ovarian carcinoma between 2000 and 2012 were identified and follow-up data was collected. In patients who survived for at least 8 years a detailed chart review was performed.

Results A total of $n=749$ patients with adequate follow-up was identified, of which $n=225$ (29%) were alive for at least 8 years after diagnosis. Median follow-up was 11.7 years. Median age at diagnosis was 53.5 years. 57% were diagnosed in advanced stage (\geq FIGO IIB). Histotyp was found to be high-grade serous in 53%, low-grade serous in 7.9%, mucinous in 7.4%, clear cell in 3.7% and endometrioid in 20% of patients. Median progression free survival was 5.0 years in early, and 2.8 years in advanced-stage patients.

Conclusion Despite ovarian carcinoma being perceived as a highly fatal disease, long-term survival is observed in a substantial number of patients and is not limited to early-stage or low-risk disease. Although prognostic factors are well established, further research of patient characteristics, genetic features and treatment modalities will help to better understand factors contributing to long-term survival. We encourage the scientific community to be aware of this special patient group, which may be key to improving our daily approach to ovarian carcinoma patients.

IGCS20_1123

145 KRAS MUTATION MAY BE ONE OF THE CHEMO-RESISTANT PHENOTYPE OF OVARIAN CLEAR CELL CARCINOMA

¹Y Konno*, ²K CHatanaka, ¹M Sakurai, ¹H Yamazaki, ¹H Asano, ¹K Ihira, ¹D Endo, ¹T Mitamura, ¹T Kato, ³Y Matsuno, ⁴Y Hatanaka, ¹H Watari. ¹Department of Obstetrics and Gynecology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan; ²Clinical Research and Medical Innovation Center, Hokkaido University Hospital, Japan; ³Department of Surgical Pathology, Hokkaido University Hospital, Japan; ⁴Research Division of Genome Companion Diagnostics, Hokkaido University Hospital, Japan

10.1136/ijgc-2020-IGCS.125

Objectives Ovarian clear cell carcinoma (OCCC) is more prevalent in Japan than western countries, and exhibits chemo-resistant phenotype and poor survival. In this study, we characterized the patient-derived xenograft (PDX) model of OCCC, and to correlate the clinical features of OCCC with KRAS mutation.

Methods We transplanted 19 primary or metastatic tumors derived from ovarian cancer patients directly into NOG mice. The comprehensive gene expression and mutation profiles as well as histologic characteristics were compared between parental tumors and PDX ones. Response to cytotoxic agents was analyzed using PDX model, and correlated with clinical outcome. In 61 consecutive OCCC patients, the genomic DNAs were extracted from FFPE, and analyzed KRAS mutations.

Results Total of 6/19 (31.6%) PDX models were established, and 2 were found to be OCCC in histological assessment. One of the OCCC PDXs had KRAS mutation, which exhibited resistance for platinum- and taxane-drugs and the patient had poor clinical outcome. The other PDX tumor without KRAS mutation was sensitive to cytotoxic agents and the patient showed good clinical outcome. Then we correlated KRAS mutations with their clinical features in OCCC. From 13 samples, we detected KRAS mutations (21%). Except for one patient, KRAS mutated OCCC had stage I diseases. Two patients experienced recurrences, and both of them had no response to conventional chemotherapy. They showed significantly worse overall survival than other recurrent OCCC patients without KRAS mutation.

Conclusions KRAS mutation may be one of the chemo-resistant phenotypes in OCCC.

IGCS20_1124

146 PROGNOSTIC SIGNIFICANCE OF HISTOLOGIC SQUAMOUS METAPLASIA AND IMMUNOHISTOCHEMICAL STAINING PATTERNS OF β -CATENIN AND P53 IN BIOPSY-PROVEN ENDOMETRIAL INTRAEPITHELIAL NEOPLASIA

¹J Wong*, ²R Whitaker, ³K Strickland, ²RA Previs. ¹Duke University School of Medicine, USA; ²Duke University Medical Center, Division of Gynecologic Oncology, USA; ³Duke University Medical Center, Department of Pathology, USA

10.1136/ijgc-2020-IGCS.126

Background Endometrial intraepithelial neoplasia (EIN) is a monoclonal proliferation of endometrial glands that can